Strong Funding Momentum EPICS Therapeutics recently secured €12 million in Series A financing, demonstrating investor confidence and providing ample resources to expand its oncology pipeline and accelerate drug development efforts.

Leadership Transition The appointment of Graeme Fraser PhD as CEO signals strategic leadership and potential for growth, making the company an attractive partner for organizations seeking innovative oncology solutions.

Focus on RNA Epigenetics Specializing in RNA epigenetic mechanisms involved in cancer, EPICS is positioned at the forefront of a cutting-edge field, offering opportunities to collaborate with researchers and clinical partners targeting high unmet medical needs.

Early Revenue Stage With current revenues between zero and one million dollars, EPICS presents an opportunity for early-stage engagement, with potential to support its R&D initiatives and ride the growth trajectory.

Strategic Collaborations Having partnered with Ogeda and maintaining active research operations, EPICS is open to forming new alliances with biotech and pharma companies focused on innovative cancer therapeutics and RNA targeting technologies.